Skip to main content
PMC home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2002 Aug;94(8 Suppl):7S–15S.

Diabetes mellitus and hypertension: key risk factors for kidney disease.

Janice P Lea 1, Susanne B Nicholas 1
PMCID: PMC2594170  PMID: 12152917

Abstract

The incidence of end-stage renal disease (ESRD) in the US is rising at an alarming rate, with the largest increase among African-American populations. The key risk factors for kidney disease are hypertension and diabetes, which are both becoming more prevalent in the US, and particularly in African Americans. Although African Americans make up 12.6% of the US population, the incidence of diabetes-related ESRD is four times higher than for whites, and the prevalence of ESRD due to hypertension is twice that of white patients. Approximately 30 to 40% of all patients with diabetes will develop nephropathy and many will progress to ESRD, necessitating dialysis or kidney transplantation. Recent studies in patients with type 2 diabetes indicate a significant delay in progression or development of diabetic nephropathy following blockade of the renin-angiotensin-aldosterone system with the use of angiotensin receptor antagonists. Early intervention in patients with hypertension is necessary to prevent kidney damage, and data from the African American Study of Kidney Disease and Hypertension suggest that angiotensin-converting enzyme inhibitors are effective in this population. Although African-American patients receiving hemodialysis appear to have increased survival compared with whites, racial factors and poor access to medical care contribute to the increased risk of kidney disease in minorities. A concerted effort is necessary to raise awareness in minority populations and provide strategies for prevention and early treatment thereby attenuating the increasing prevalence of kidney failure in these groups.

Full text

PDF
7S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adrogué H. J., Wesson D. E. Role of dietary factors in the hypertension of African Americans. Semin Nephrol. 1996 Mar;16(2):94–101. [PubMed] [Google Scholar]
  2. Agodoa L. Y., Appel L., Bakris G. L., Beck G., Bourgoignie J., Briggs J. P., Charleston J., Cheek D., Cleveland W., Douglas J. G. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001 Jun 6;285(21):2719–2728. doi: 10.1001/jama.285.21.2719. [DOI] [PubMed] [Google Scholar]
  3. Brenner B. M., Cooper M. E., de Zeeuw D., Grunfeld J. P., Keane W. F., Kurokawa K., McGill J. B., Mitch W. E., Parving H. H., Remuzzi G. The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst. 2000 Dec;1(4):328–335. doi: 10.3317/jraas.2000.062. [DOI] [PubMed] [Google Scholar]
  4. Burt V. L., Whelton P., Roccella E. J., Brown C., Cutler J. A., Higgins M., Horan M. J., Labarthe D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995 Mar;25(3):305–313. doi: 10.1161/01.hyp.25.3.305. [DOI] [PubMed] [Google Scholar]
  5. Caetano E. R., Zatz R., Saldanha L. B., Praxedes J. N. Hypertensive nephrosclerosis as a relevant cause of chronic renal failure. Hypertension. 2001 Aug;38(2):171–176. doi: 10.1161/01.hyp.38.2.171. [DOI] [PubMed] [Google Scholar]
  6. Chaiken R. L., Eckert-Norton M., Bard M., Banerji M. A., Palmisano J., Sachimechi I., Lebovitz H. E. Hyperfiltration in African-American patients with type 2 diabetes. Cross-sectional and longitudinal data. Diabetes Care. 1998 Dec;21(12):2129–2134. doi: 10.2337/diacare.21.12.2129. [DOI] [PubMed] [Google Scholar]
  7. Coresh J., Wei G. L., McQuillan G., Brancati F. L., Levey A. S., Jones C., Klag M. J. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2001 May 14;161(9):1207–1216. doi: 10.1001/archinte.161.9.1207. [DOI] [PubMed] [Google Scholar]
  8. Estacio R. O., Jeffers B. W., Gifford N., Schrier R. W. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000 Apr;23 (Suppl 2):B54–B64. [PubMed] [Google Scholar]
  9. Estacio R. O., Jeffers B. W., Hiatt W. R., Biggerstaff S. L., Gifford N., Schrier R. W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998 Mar 5;338(10):645–652. doi: 10.1056/NEJM199803053381003. [DOI] [PubMed] [Google Scholar]
  10. Fogo A., Breyer J. A., Smith M. C., Cleveland W. H., Agodoa L., Kirk K. A., Glassock R. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int. 1997 Jan;51(1):244–252. doi: 10.1038/ki.1997.29. [DOI] [PubMed] [Google Scholar]
  11. Freedman B. I., Iskandar S. S., Appel R. G. The link between hypertension and nephrosclerosis. Am J Kidney Dis. 1995 Feb;25(2):207–221. doi: 10.1016/0272-6386(95)90001-2. [DOI] [PubMed] [Google Scholar]
  12. Goldschmid M. G., Domin W. S., Ziemer D. C., Gallina D. L., Phillips L. S. Diabetes in urban African-Americans. II. High prevalence of microalbuminuria and nephropathy in African-Americans with diabetes. Diabetes Care. 1995 Jul;18(7):955–961. doi: 10.2337/diacare.18.7.955. [DOI] [PubMed] [Google Scholar]
  13. Gower Barbara A. Syndrome X in children: Influence of ethnicity and visceral fat. Am J Hum Biol. 1999;11(2):249–257. doi: 10.1002/(SICI)1520-6300(1999)11:2<249::AID-AJHB12>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  14. Jamerson K. A. Prevalence of complications and response to different treatments of hypertension in African Americans and white Americans in the U.S.. Clin Exp Hypertens. 1993 Nov;15(6):979–995. doi: 10.3109/10641969309037086. [DOI] [PubMed] [Google Scholar]
  15. Jamerson K. A. Rationale for angiotensin II receptor blockers in patients with low-renin hypertension. Am J Kidney Dis. 2000 Sep;36(3 Suppl 1):S24–S30. doi: 10.1053/ajkd.2000.9688. [DOI] [PubMed] [Google Scholar]
  16. Jones C. A., McQuillan G. M., Kusek J. W., Eberhardt M. S., Herman W. H., Coresh J., Salive M., Jones C. P., Agodoa L. Y. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis. 1998 Dec;32(6):992–999. doi: 10.1016/s0272-6386(98)70074-5. [DOI] [PubMed] [Google Scholar]
  17. Klag M. J., Whelton P. K., Randall B. L., Neaton J. D., Brancati F. L., Ford C. E., Shulman N. B., Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996 Jan 4;334(1):13–18. doi: 10.1056/NEJM199601043340103. [DOI] [PubMed] [Google Scholar]
  18. Klahr S., Levey A. S., Beck G. J., Caggiula A. W., Hunsicker L., Kusek J. W., Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994 Mar 31;330(13):877–884. doi: 10.1056/NEJM199403313301301. [DOI] [PubMed] [Google Scholar]
  19. Kohler K. A., McClellan W. M., Ziemer D. C., Kleinbaum D. G., Boring J. R. Risk factors for microalbuminuria in black americans with newly diagnosed type 2 diabetes. Am J Kidney Dis. 2000 Nov;36(5):903–913. doi: 10.1053/ajkd.2000.19080. [DOI] [PubMed] [Google Scholar]
  20. Lewis E. J., Hunsicker L. G., Bain R. P., Rohde R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11;329(20):1456–1462. doi: 10.1056/NEJM199311113292004. [DOI] [PubMed] [Google Scholar]
  21. Martins D., Norris K. Combating diabetic nephropathy with drug therapy. Curr Diab Rep. 2001 Oct;1(2):148–156. doi: 10.1007/s11892-001-0027-5. [DOI] [PubMed] [Google Scholar]
  22. Maschio G., Alberti D., Janin G., Locatelli F., Mann J. F., Motolese M., Ponticelli C., Ritz E., Zucchelli P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996 Apr 11;334(15):939–945. doi: 10.1056/NEJM199604113341502. [DOI] [PubMed] [Google Scholar]
  23. Mokdad A. H., Ford E. S., Bowman B. A., Nelson D. E., Engelgau M. M., Vinicor F., Marks J. S. Diabetes trends in the U.S.: 1990-1998. Diabetes Care. 2000 Sep;23(9):1278–1283. doi: 10.2337/diacare.23.9.1278. [DOI] [PubMed] [Google Scholar]
  24. Parving H. H., Lehnert H., Bröchner-Mortensen J., Gomis R., Andersen S., Arner P., Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):870–878. doi: 10.1056/NEJMoa011489. [DOI] [PubMed] [Google Scholar]
  25. Peterson J. C., Adler S., Burkart J. M., Greene T., Hebert L. A., Hunsicker L. G., King A. J., Klahr S., Massry S. G., Seifter J. L. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995 Nov 15;123(10):754–762. doi: 10.7326/0003-4819-123-10-199511150-00003. [DOI] [PubMed] [Google Scholar]
  26. Reddan D. N., Szczech L. A., Klassen P. S., Owen W. F., Jr Racial inequity in America's ESRD program. Semin Dial. 2000 Nov-Dec;13(6):399–403. doi: 10.1046/j.1525-139x.2000.00109.x. [DOI] [PubMed] [Google Scholar]
  27. Redon J., Liao Y., Lozano J. V., Miralles A., Baldo E., Cooper R. S. Factors related to the presence of microalbuminuria in essential hypertension. Am J Hypertens. 1994 Sep;7(9 Pt 1):801–807. doi: 10.1093/ajh/7.9.801. [DOI] [PubMed] [Google Scholar]
  28. Rostand S. G., Kirk K. A., Rutsky E. A., Pate B. A. Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med. 1982 May 27;306(21):1276–1279. doi: 10.1056/NEJM198205273062106. [DOI] [PubMed] [Google Scholar]
  29. Rostand S. G. US minority groups and end-stage renal disease: a disproportionate share. Am J Kidney Dis. 1992 May;19(5):411–413. doi: 10.1016/s0272-6386(12)80946-2. [DOI] [PubMed] [Google Scholar]
  30. Ruggenenti P., Perna A., Gherardi G., Gaspari F., Benini R., Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet. 1998 Oct 17;352(9136):1252–1256. doi: 10.1016/s0140-6736(98)04433-x. [DOI] [PubMed] [Google Scholar]
  31. Ruilope L. M., Salvetti A., Jamerson K., Hansson L., Warnold I., Wedel H., Zanchetti A. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol. 2001 Feb;12(2):218–225. doi: 10.1681/ASN.V122218. [DOI] [PubMed] [Google Scholar]
  32. Schlessinger S. D., Tankersley M. R., Curtis J. J. Clinical documentation of end-stage renal disease due to hypertension. Am J Kidney Dis. 1994 May;23(5):655–660. doi: 10.1016/s0272-6386(12)70275-5. [DOI] [PubMed] [Google Scholar]
  33. Sharma K., Ziyadeh F. N., Alzahabi B., McGowan T. A., Kapoor S., Kurnik B. R., Kurnik P. B., Weisberg L. S. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes. 1997 May;46(5):854–859. doi: 10.2337/diab.46.5.854. [DOI] [PubMed] [Google Scholar]
  34. Sica D. A., Douglas J. G. The African American Study of Kidney Disease and Hypertension (AASK): new findings. J Clin Hypertens (Greenwich) 2001 Jul-Aug;3(4):244–251. doi: 10.1111/j.1524-6175.2001.00474.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Sica Domenic A., Bakris George L. Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options. J Clin Hypertens (Greenwich) 2002 Jan-Feb;4(1):52–57. doi: 10.1111/j.1524-6175.2002.00749.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Suthanthiran M., Khanna A., Cukran D., Adhikarla R., Sharma V. K., Singh T., August P. Transforming growth factor-beta 1 hyperexpression in African American end-stage renal disease patients. Kidney Int. 1998 Mar;53(3):639–644. doi: 10.1046/j.1523-1755.1998.00858.x. [DOI] [PubMed] [Google Scholar]
  37. Thaler L. M., El-Kebbi I. M., Ziemer D. C., Gallina D. L., Dunbar V. G., Phillips L. S. High prevalence of albuminuria among African-Americans with short duration of diabetes. Diabetes Care. 1998 Sep;21(9):1576–1577. doi: 10.2337/diacare.21.9.1576. [DOI] [PubMed] [Google Scholar]
  38. The Worldwide Burden of Diabetes. Proceedings of a workshop. Phoenix, Arizona, USA. 6-7 December 1996. Diabetes Care. 1998 Dec;21 (Suppl 3):C1–52. [PubMed] [Google Scholar]
  39. Vollmer W. M., Sacks F. M., Ard J., Appel L. J., Bray G. A., Simons-Morton D. G., Conlin P. R., Svetkey L. P., Erlinger T. P., Moore T. J. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med. 2001 Dec 18;135(12):1019–1028. doi: 10.7326/0003-4819-135-12-200112180-00005. [DOI] [PubMed] [Google Scholar]
  40. Walker W. G., Neaton J. D., Cutler J. A., Neuwirth R., Cohen J. D. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA. 1992 Dec 2;268(21):3085–3091. [PubMed] [Google Scholar]
  41. Weisstuch J. M., Dworkin L. D. Does essential hypertension cause end-stage renal disease? Kidney Int Suppl. 1992 May;36:S33–S37. [PubMed] [Google Scholar]
  42. Young C. J., Gaston R. S. Renal transplantation in black Americans. N Engl J Med. 2000 Nov 23;343(21):1545–1552. doi: 10.1056/NEJM200011233432107. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES